Search

Your search keyword '"Claire Bombardier"' showing total 384 results

Search Constraints

Start Over You searched for: Author "Claire Bombardier" Remove constraint Author: "Claire Bombardier"
384 results on '"Claire Bombardier"'

Search Results

1. Cardiovascular Risk Factors and the Risk of Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results From the Ontario Best Practices Research Initiative

2. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative

3. Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada

4. Comorbidities Before and After the Diagnosis of Rheumatoid Arthritis: A Matched Longitudinal Study

5. Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort.

6. Effect of active TENS versus de-tuned TENS on walking capacity in patients with lumbar spinal stenosis: a randomized controlled trial

7. Cardiovascular risk factors are negatively associated with rheumatoid arthritis disease outcomes

8. Health care costs of rheumatoid arthritis: A longitudinal population study.

9. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment.

10. ECU convention 2017 research presentations

11. Recommendations for the Appropriate Use of Anti-Inflammatory Drugs in the Era of the Coxibs: Defining the Role of Gastroprotective Agents

12. Bridging the Gap Between Symptom Onset and Diagnosis in Axial Spondyloarthritis

13. Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry

15. Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI)

16. Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts

17. Canadian Rheumatology Association Living Guidelines for the Pharmacological Management of Rheumatoid Arthritis With Disease-Modifying Antirheumatic Drugs

18. Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study

19. Medical cannabis use by rheumatology patients in routine clinical care: results from The Ontario Best Practices Research Initiative

20. Comorbidities Before and After the Diagnosis of Rheumatoid Arthritis: A Matched Longitudinal Study

21. Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort

22. Interventions for tophi in gout

23. Differential influence of Clinical Disease Activity Index components based on disease state in rheumatoid arthritis patients: real-world results from the Ontario Best Practices Research Initiative

24. Frailty and risk of osteoporotic fractures in patients with rheumatoid arthritis: Data from the Ontario Best Practices Research Initiative

25. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results

26. Effect of a prototype lumbar spinal stenosis belt versus a lumbar support on walking capacity in lumbar spinal stenosis: a randomized controlled trial

27. OP0179 DISCONTINUATION RATE OF TOFACITINIB IS SIMILAR WHEN COMPARED TO TNF INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS: POOLED DATA FROM TWO RHEUMATOID ARTHRITIS REGISTRIES IN CANADA

28. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database

29. Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI)

30. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment

31. Response to the letter to the editor by Sabour et al. (2019) Re: 'Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: Methodological issues to avoid misinterpretation'

32. POS0449 BIOLOGICS INITIATION IN MODERATE VS SEVERE RHEUMATOID ARTHRITIS PATIENTS: PROSPECTIVE OBSERVATIONAL STUDY FROM A CANADIAN REGISTRY

33. POS0445 PHYSICIAN AND PATIENT REPORTED EFFECTIVENESS OUTCOMES ARE SIMILAR IN TOFACITINIB AND TNF INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS: DATA FROM A RHEUMATOID ARTHRITIS REGISTRY IN CANADA

34. POS0448 DISCONTINUATION RATE OF TOFACITINIB AS MONOTHERAPY IS SIMILAR COMPARED TO COMBINATION THERAPY WITH METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS: POOLED DATA FROM TWO RHEUMATOID ARTHRITIS REGISTRIES IN CANADA

35. Health care costs of rheumatoid arthritis: A longitudinal population study

36. Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative

37. Primary Care Screening and Comorbidity Management in Rheumatoid Arthritis in Ontario, Canada

38. THU0545 THE ASSOCIATION OF RHEUMATOID ARTHRITIS WITH HEALTH CARE COSTS FROM THE PAYERS PERSPECTIVE FROM 2001-2015

39. SAT0049 DIFFERENCES BETWEEN EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS IN TIME TO ACHIEVING CDAI BUT NOT FATIGUE LOW DISEASE ACTIVITY AND REMISSION: DATA FROM THE OBRI REGISTRY

40. Patterns of Care Among Patients Referred to Rheumatologists in Ontario, Canada

41. FRI0122 REAL-WORLD SAFETY DATA FROM PATIENTS WITH RHEUMATIC DISEASES TREATED WITH CT-P13, AN INFLIXIMAB BIOSIMILAR: AN INTERIM ANALYSIS FROM AN OBSERVATIONAL STUDY

43. THU0126 FACTORS AFFECTING THE DISCREPANCY BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OVER TIME

44. THU0125 CARDIOVASCULAR DISEASE RISK FACTORS MAY NEGATIVELY IMPACT RHEUMATOID ARTHRITIS DISEASE OUTCOMES: FINDINGS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE

45. THU0163 A DESCRIPTIVE ANALYSIS OF LONGITUDINAL CHANGES IN RELATIVE MARKET SHARE PROPORTIONS OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS: DATA FROM THE OBRI DATABASE

46. Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI)

47. The Effect of Triage Assessments on Identifying Inflammatory Arthritis and Reducing Rheumatology Wait Times in Ontario

48. ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)

49. Cardiovascular risk factors are negatively associated with rheumatoid arthritis disease outcomes

50. Effect of TENS Versus Placebo on Walking Capacity in Patients With Lumbar Spinal Stenosis: A Protocol for a Randomized Controlled Trial

Catalog

Books, media, physical & digital resources